| Menopausal syndrome
Estrogel vs Lynkuet
Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.Deep comparison between: Estrogel vs Lynkuet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLynkuet has a higher rate of injection site reactions vs Estrogel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lynkuet but not Estrogel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Estrogel
Lynkuet
At A Glance
Topical
Daily
Estrogen
Oral
Daily
NK1/NK3 receptor antagonist
Indications
- Menopausal syndrome
- Postmenopausal atrophic vaginitis
- Menopausal syndrome
Dosing
Menopausal syndrome, Postmenopausal atrophic vaginitis EstroGel 0.06% 1.25 g (0.75 mg estradiol) once daily applied as a thin layer over the entire arm on the inside and outside from wrist to shoulder.
Menopausal syndrome 120 mg (two 60 mg capsules) orally once daily at bedtime, with or without food; swallow capsules whole.
Contraindications
- Abnormal genital bleeding of unknown etiology
- Current or history of breast cancer
- Current or history of estrogen-dependent neoplasia
- Active DVT, PE, or history of these conditions
- Active arterial thromboembolic disease (e.g., stroke or MI), or history of these conditions
- Known anaphylactic reaction, angioedema, or hypersensitivity to EstroGel or any excipient
- Hepatic impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Pregnancy (exposure may cause pregnancy loss or stillbirth)
Adverse Reactions
Most common (>=5%) Breast pain, headache, flatulence
Serious Cardiovascular disorders, malignant neoplasms
Postmarketing Endometrial cancer, breast cancer, deep vein thrombosis, myocardial ischemia, phlebitis, nausea, alopecia, rash, retinal vein occlusion, meningioma, angioedema, hepatitis
Most common (>=2%) headache, fatigue, dizziness, somnolence, abdominal pain, rash, diarrhea, muscle spasms
Serious CNS depressant effect and daytime impairment, hepatic transaminase elevations
Pharmacology
Estradiol is the principal intracellular human estrogen, acting through binding to nuclear receptors in estrogen-responsive tissues; it modulates pituitary gonadotropin secretion via a negative feedback mechanism to reduce elevated LH and FSH levels seen in postmenopausal women.
Elinzanetant is an NK1 and NK3 receptor antagonist that inhibits Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, modulating neuronal activity in thermoregulation associated with hot flashes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Estrogel
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (9/12)
Lynkuet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (5/12)
UnitedHealthcare
Estrogel
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Lynkuet
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Estrogel
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Lynkuet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Estrogel.
No savings programs available for Lynkuet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EstrogelView full Estrogel profile
LynkuetView full Lynkuet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.